Search Results
Challenges in the field of PARPi treatment for mCRPC
PARP inhibitors for the treatment of metastic castration-resistant prostate cancer
PROpel: olaparib plus abiraterone as 1L treatment for metastatic CRPC
Combination therapies for the treatment of prostate cancer
ASCO 2021: Latest on PARPi and other treatments for mCRPC
Point-Counterpoint: Management of mCRPC
The evolving treatment landscape of mHSPC and mCRPC
The PROpel clinical trial exploring olaparib plus abiraterone in mCRPC
CASPAR: the addition of rucaparib to enzalutamide for the treatment of mCRPC
ATLANTIS rucaparib arm: maintenance PARPi following chemotherapy for mUC
BRCA & PARP Inhibitors: Targeted Chemotherapy | #MarkScholzMD #AlexScholz @PCRI
Overcoming resistance to PARPi in BRCA1-deficient breast cancer with STING agonists
